Views
1 year ago

2013 Scientific Report

  • Text
  • Report
  • Institute
  • Clinical
  • Molecular
  • Scientific
  • Tumor
  • Laboratory
  • Signaling

VARI |

VARI | 2013 Research Interests VARI-ClinXus, LLC, is a West Michigan translational research organization dedicated to benefiting human health and improving patient’s lives through early-phase and molecular-based trials that are fundamental to personalized medicine. VARI-ClinXus works with community partner institutions that are highly credentialed in areas of health care, early clinical development, clinical research, and academics. Through our network, we are able to provide client organizations with the many advantages of collective expertise to facilitate innovative clinical trials of diagnostics, devices, and biological agents and bring them to market in a more efficient time frame. We offer an integrated suite of services that includes protocol and project design, clinical trial development and implementation, state-of-the-art patient facilities and support, extensive molecular profiling capabilities, and a full breadth of integrated IT infrastructure. The comprehensive expertise of our partner institutions extends across a wide range of specialties, with an emphasis on oncologic and neurodegenerative medicine. Current partners include Advanced Radiology Services, Borgess Research Institute, Bronson Healthcare, Cancer and Hematology Centers of West Michigan, Ferris State University, Grand Valley Medical Specialists, Grand Valley State University, Innovative Analytics, Jasper Clinical Research & Development, Metro Health Hospital, Michigan Institute for Clinical & Health Research, Michigan State University, MPI Research, Saint Mary’s Health Care, and Spectrum Health hospitals. We have partnered with the Critical Path Institute’s Predictive Safety Testing Consortium (PSTC) in several capacities, and we provide clinical advice and support for PSTC’s clinical efforts in the evaluation and qualification of new biomarkers to assist in the safety of drug development. The PSTC’s mission is to bring pharmaceutical companies together to validate each other’s safety testing methods. 9

John F. Bender, Pharm.D. Clinical Operations Dr. Bender holds a B.S. in biology from Mount Saint Mary’s College, a B.S. in pharmacy from the University of Maryland, and a Pharm.D. from the University of Utah. He worked at Parke-Davis as director of clinical research – oncology for over 20 years. Dr. Bender also served as senior vice-president of clinical research and of research and development at two biopharmaceutical companies in San Diego that focused on cancer treatments. He is currently the Clinical Operations Director at the Van Andel Research Institute. He is also an Adjunct Assistant Professor of Clinical Pharmacy with the Ferris State College of Pharmacy in Grand Rapids. Research Interests As VARI Clinical Operations Director, Dr. Bender coordinates the development of oncology clinical trials to accelerate translational research studies in Grand Rapids. He provides translational research support to VARI research, with active projects currently in eight labs. An effort underway is to establish a clinical trial center for VARI. Dr. Bender has an effective network of colleagues within Michigan and beyond, and he fosters productive interactions between VARI researchers, outside investigators, and the pharmaceutical and clinical communities. Staff Ashley Rodriguez 10

Publications by Year